Search

Displaying results 2001 - 2010 of 10000 in total
  1. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245159,L40114] In approximately 90% of cases, patients develop immunoglobulin M (IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and are therefore … [A245154] Notably, none of these agents are approved for use in the treatment of CAD.

  2. Target

    RuvB-like 2

    go.drugbank.com/bio_entities/BE0009019
    TargetHumans

    May play a role in regulating the composition of the U5 snRNP complex (PubMed:28561026) … Proposed core component of the chromatin remodeling INO80 complex which exhibits DNA- and nucleosome-activated ATPase activity and catalyzes ATP-dependent nucleosome sliding (PubMed:16230350, PubMed:21303910

    Synonyms: INO80 complex subunit J
  3. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    [L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126] … [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

  4. Drug

    Penicillamine

    go.drugbank.com/drugs/DB00859
    ApprovedInvestigational

    It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    _C. botulinum_ is known to produce toxins that can cause botulism in humans. … DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent.

  6. Drug

    Dabigatran etexilate

    go.drugbank.com/drugs/DB06695
    ApprovedInvestigational

    [A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. … [A177463] In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022]

  7. Drug

    Anthrax vaccine

    go.drugbank.com/drugs/DB11003
    ApprovedInvestigational

    [L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas … [L47561] There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.

    Categories: Complex Mixtures
  8. Drug

    Viomycin

    go.drugbank.com/drugs/DB06827
    Approved

    These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was derived from the actinomycete _Streptomyces puniceus_.

  9. Drug

    Ustekinumab

    go.drugbank.com/drugs/DB05679
    ApprovedInvestigational

    L52830] and Wezlana [L52073] in Canada, and Uzpruvo in the EU. … In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults.

    Products: Stelara Solution for Injection in Pre-Filled Syringe 90 mg/1 mL, STELARA 90MG/1ML SOLUTION FOR INJECTION IN PREFILLED SYRINGE
  10. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alfa and beta formulations. … Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells.

    Products: EPORATIO 20000 I E /1ML, EPORATIO 1000 I E /0.5ML